-
Iran condemned as UN maritime body holds emergency talks on Mideast shipping
-
Iraqi Kurdish shepherds stoic in face of yet another war
-
Iran women's football team return after asylum tussle
-
US launches new era of drug war with Latin American allies
-
How many cargo ships are passing Hormuz strait?
-
'Free France': Macron reveals name of Europe's largest warship
-
Oil surges as Iran gas facilities hit, stocks slide
-
Foreign press group slams Israeli police for breaking journalist's wrist
-
McIlroy happy with back injury recovery as Masters looms
-
Vinicius 'should be loved by everyone' says Donnarumma after celebration row
-
Iran was not rebuilding nuclear enrichment, US intelligence finds
-
Carrick urges England boss Tuchel to call up United trio
-
Three sporting champions to be stripped of titles for non-doping reasons
-
Chilean GDP beats 2025 forecast despite mining dip
-
Storms, warm seas drove sudden drop in Antarctic ice: study
-
Aston Villa want to be more than a 'maybe team' in quest for Europa League
-
Trump administration takes steps to curb energy cost hikes
-
Vaccines facing misinformation spike: WHO experts
-
Pakistan announces Eid 'pause' in conflict with Afghanistan
-
'Happened so fast': UK students panicked by meningitis outbreak
-
WNBA, players union agree 'transformative' labor deal: reports
-
Global music market grows, calls for AI compensation: industry body
-
Maiduguri bombings follow surge of jihadist violence in Nigeria
-
Belgian court suspends TotalEnergies climate trial
-
Troubled waters: Thai fishermen marooned by rising fuel costs
-
Doku adamant Man City still have plenty to play for after Champions League exit
-
Afghanistan vows to avenge deadly Kabul bombing but says open to talks
-
Nigerian president meets royals on 'historic' UK state visit
-
South Lebanon residents flee death and destruction
-
Buttler ready to continue England career despite 'poor' T20 World Cup
-
Why convoys cannot fully protect oil tankers from Iran attacks
-
UK PM leads efforts to halt deadly meningitis spread
-
EU lawmakers back ban on sexualised AI deepfakes
-
Stripping Senegal of AFCON title a 'disgrace for Africa' say fans
-
Under Hezbollah fire, people in north Israel hope for better days
-
Iran women's football team cross Turkish border to head home: AFP
-
Fear in central Beirut as Israel strikes, with and without warning
-
'France is wild': Macron to unveil name of Europe's largest warship
-
Arsenal's Trossard says Leverkusen win ideal ahead of League Cup final
-
Israel conducts wave of strikes on Beirut
-
Seven-year term sought for Norway princess's son for alleged rapes
-
US govt says Anthropic AI an 'unacceptable risk' to military
-
Head of victorious Nepal party hails 'win for the country'
-
UN maritime body kicks off emergency talks on Mideast shipping
-
Israel says killed Iran intel chief, tells military to hunt down officials
-
China tech giant Tencent bets on AI agents
-
AFCON stripping of Senegal's title a 'disgrace for Africa' say fans
-
Japan thrash South Korea 4-1 to set up Women's Asian Cup final with Australia
-
Fernandez uncertain over Chelsea future after Champions League exit
-
Iran women's football team arrive in eastern Turkey, heading home
VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street
Twelve months of national and global coverage to include long-form interviews, earned media, television commercials, iconic outdoor billboards, and accredited investor events
NEW YORK CITY, NEW YORK / ACCESS Newswire / February 5, 2026 / Vivos Therapeutics, Inc. (NASDAQ:VVOS), a medical technology company focused on innovative solutions for breathing and sleep disorders, today announced that it has entered into a 12-part media series agreement with New to The Street, one of the longest-running business television and digital media platforms serving public companies in the U.S. and international markets.
The 12-month series is designed to expand Vivos Therapeutics' visibility among investors, healthcare professionals, and strategic partners through a comprehensive, multi-channel media strategy spanning linear television, digital platforms, social media, outdoor advertising, and live investor engagement.
As part of the agreement, Vivos Therapeutics will receive:
Long-form broadcast interviews distributed nationally and internationally
Earned media coverage supporting corporate milestones and clinical positioning
Television commercials airing as sponsored programming alongside New to The Street broadcasts
Iconic outdoor billboard placements in high-impact financial and metropolitan locations
Accredited investor events, providing direct engagement with screened, invitation-only investor audiences
The series will allow Vivos Therapeutics to consistently communicate its clinical progress, commercial execution, and long-term growth strategy throughout the year.
"Partnering with New to The Street provides a sustained, credible platform to communicate our story to a broad audience of investors and stakeholders," said a spokesperson for Vivos Therapeutics. "This multi-part series supports our commitment to education, transparency, and long-term shareholder engagement."
The first segment in the Vivos Therapeutics series is expected to begin airing in the coming weeks, with coverage continuing throughout the 12-month term.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ:VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment solutions for breathing and sleep disorders arising from certain dentofacial abnormalities, including obstructive sleep apnea (OSA) and snoring in adults and children.
Vivos' proprietary technologies have been cleared by the U.S. Food and Drug Administration (FDA) for use in adult patients diagnosed with all severity levels of OSA, as well as moderate-to-severe OSA in pediatric patients ages 6 to 17. The company's groundbreaking Complete Airway Repositioning and Expansion (CARE) devices represent the only FDA 510(k)-cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children.
OSA affects more than one billion people worldwide, with an estimated 80% or more remaining undiagnosed. Beyond disrupted sleep, OSA is closely linked to numerous serious chronic health conditions. While legacy treatments such as CPAP have addressed symptoms, they are often mechanistic and may not address the underlying anatomical causes of the disorder.
Founded in 2016 and headquartered in Littleton, Colorado, Vivos is working to transform the standard of care for sleep-disordered breathing through innovative technology, education, and strategic collaborations with sleep healthcare providers. The company's comprehensive approach-known as The Vivos Method-offers a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution, designed to address the root causes of OSA and improve long-term patient outcomes.
For more information, visit www.vivos.com.
About New to The Street
New to The Street is a 17-year-old, nationally and internationally syndicated business television brand that broadcasts weekly on Bloomberg Television as sponsored programming, featuring client interviews and television commercials. The program airs across the United States, MENA (Middle East & North Africa), and Latin America, delivering consistent global exposure.
In addition to its linear television distribution, New to The Street operates one of the largest YouTube subscriber channels in the financial and business media space, with over 4.4 million subscribers on New to The Street TV. The platform combines long-form interviews, earned media, digital amplification, and iconic outdoor advertising to deliver predictable, high-impact visibility for its clients.
https://youtube.com/@newtothestreettv
Media Contact:
Monica Brennan
New to The Street
[email protected]
SOURCE: New to The Street
View the original press release on ACCESS Newswire
Y.Nakamura--AMWN